查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1933368

全球犬類疫苗市場：市場規模、佔有率、成長率、產業分析、依類型、應用和地區劃分的考察、未來預測（2026-2034）

Canine Vaccines Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2026-2034
出版日期: | 出版商: Fortune Business Insights Pvt. Ltd. | 英文 167 Pages | 商品交期: 請詢問到貨日

價格

犬類疫苗市場成長因素

預計2025年全球犬類疫苗市場規模將達到19.5億美元，2026年將成長至20.5億美元，到2034年將達到36.4億美元，預測期內年複合成長率（CAGR）為7.42%。北美地區將引領市場，2025年市場佔有率將達到44.85%，這主要得益於其先進的獸醫基礎設施、不斷成長的寵物擁有率以及人們對犬類疾病預防的日益重視。寵物人性化程度的提高、可支配收入的增加以及犬隻預防保健的普及，都推動了該市場的強勁成長。

市場上的主要參與者，包括 Zoetis Services LLC、Merck & Co., Inc.、Elanco、Boehringer Ingelheim International GmbH、Virbac、Ceva、Bioveta a.s.、Indian Immunologicals Ltd.、HIPRA 和 Brilliant Bio Pharma，均提供創新的疫苗解決方案，並拓展其全球業務。例如，耶魯大學醫學院於2024年 3月研發出一種針對犬類 EGFR/HER2 蛋白的癌症疫苗，顯示人們對犬類健康新型疫苗的興趣日益濃厚。

市場動態

驅動因素：全球寵物主人數量的不斷成長以及他們日益增強的對先進犬類醫療保健的投資意願是市場成長的關鍵驅動因素。根據全球動物健康協會（GAHA）2022年 9月發布的報告，美國家庭飼養的寵物犬數量估計約為 8,500萬隻，這表明疫苗接種具有巨大的潛力。人們對疾病預防（包括犬窩咳、萊姆病和犬流感）的認識不斷提高，進一步推動了市場成長。

限制因素：犬主對疫苗接種的猶豫仍然是一個主要挑戰。對疫苗安全性和副作用的擔憂，以及對定期接種疫苗必要性的認識不足，導致疫苗接種率下降。根據全球疫苗免疫聯盟（GAVI）2025年 1月發布的報告，4%的犬和 12%的貓仍未接種狂犬病疫苗，這反映出人們持續的猶豫和市場限制。

機會：新型聯合疫苗的研發和核准將實現對多種疾病的廣譜保護。2025年 7月，Eli Lilly and Company（Elanco）採用 PureFil 技術的犬流感聯合疫苗 "TruCan Ultra CIV H3N2/H3N8" 獲得美國農業部（USDA）的批准。這些創新將提高便利性，減少副作用，並加強疾病的全面預防。

挑戰：獸醫診所就診量下降和專業人員短缺影響市場成長。2021年至2023年間，客戶就診量下降了2.7%。此外，到2030年，全球獸醫缺口約15,000人，難以滿足預計的需求。這些因素阻礙了疫苗的普及，並給行業利益相關者帶來了挑戰。

市場趨勢

更容易接種的疫苗（例如鼻內疫苗）的研發興起。這些疫苗可以減輕寵物的壓力，並使其快速產生免疫反應，而無需專業人員操作。例如，2025年3月，Zoetis Services LLC推出了Vanguard B，這是一種針對犬窩咳（博德氏菌）的鼻內疫苗，這反映了疫苗市場正朝著高效便捷的方向發展。

市場區隔分析

依技術分類：

  • 滅活疫苗因其卓越的安全性和獸醫認可度高而日益普及。例如，Boehringer Ingelheim於2024年11月推出了Eurican L4，用於預防鉤端螺旋體病。
  • 減毒活疫苗可提供長期免疫力，同時減少加強劑的接種次數。Merck公司的Novivac Canin1-DAPPv可同時預防多種病毒感染。
  • 重組疫苗和其他疫苗因其安全性和精準靶向性而持續成長。

依疾病類型分類：

  • 犬流感疫苗持續佔據主導地位，這主要得益於病例數的增加和新核准疫苗的出現（例如，Novivac NXT犬流感H3N2疫苗於2024年6月獲準）。
  • 狂犬病疫苗在全球疫苗接種計畫中仍然非常重要。截至2022年6月，孟加拉已使用了225萬劑狂犬病疫苗，為81.57%的流浪犬接種了疫苗。
  • 由於疾病發生率上升和預防性護理的廣泛應用，萊姆病和鉤端螺旋體病的發生率也在上升。

依給藥途徑：

  • 口服疫苗因對獸醫和寵物都方便，已成為主流。Merck公司於2022年9月推出了Nobivac Intra-Trac口服BbPi疫苗。
  • 鼻腔疫苗方便快捷，可減輕壓力，因此越來越受歡迎。
  • 由於政府支持的疫苗接種計劃，注射疫苗仍然佔據相當大的市場佔有率。

依通路劃分：

  • 獸醫診所憑藉其先進的設施和寵物主人的偏好，在市場中扮演著主導角色。例如，隸屬於皇家獸醫學院的博蒙特、塞恩斯伯里動物醫院於2025年8月獲得了 "犬類友善型" 認證。
  • 得益於VetRec等人工智慧輔助解決方案，獸醫診所蓬勃發展。 VetRec於2025年1月與Bond Vet達成合作。
  • 藥局、藥局和其他通路的成長較為溫和。

區域展望

  • 北美：到2025年，北美市場規模達到8.8億美元，其中美國憑藉其先進的醫療保健體系和政府支持，將引領市場成長。
  • 歐洲：由於寵物主人數量的不斷增加，預計歐洲市場將顯著成長。 在英國，28%的成年人養狗（PDSA2024）。
  • 亞太地區：預計年複合成長率最高，這主要得益於新興市場和策略擴張（例如，Biobeta於2024年9月與印度Betina Healthcare建立合作關係）。 拉丁美洲、中東和非洲：預期成長較為溫和，這主要得益於政府主導的疫苗接種計畫。例如：Boehringer Ingelheim在肯亞進行的狂犬病預防活動（於2024年12月實施）。

目錄

第1章 引言

第2章 執行摘要

第3章 市場動態

  • 市場驅動因素
  • 市場限制因素
  • 市場機會
  • 市場趨勢

第4章 主要考察

  • 主要國家/地區犬類疾病概覽（2025年）
  • 主要國家/地區監管狀況（2025年）
  • 犬類疾病疫苗接種概覽
  • 主要公司新技術應用
  • 關鍵趨勢：併購、業務合作等

第5章 全球犬類疫苗市場分析：洞察與預測（2021-2034）

  • 市場分析、洞察與預測：依技術分類
    • 滅活疫苗
    • 減毒活疫苗
    • 重組疫苗
    • 其他
  • 市場分析、洞察與預測：依疾病類型分類
    • 犬流感
    • 萊姆病
    • 狂犬病
    • 鉤端螺旋體病
    • 其他
  • 市場分析、洞察與預測：依技術分類，依給藥途徑分類
    • 口服
    • 注射
    • 鼻腔給藥
  • 市場分析、洞察與預測：依通路分類
    • 獸醫院
    • 獸藥診所
    • 藥局和藥局
    • 其他
  • 市場分析、洞察與預測：依地區劃分
    • 北美
    • 歐洲
    • 亞太地區
    • 拉丁美洲
    • 中東和非洲

第6章 北美犬類疫苗市場分析：洞察與預測（2021-2034）

  • 依國家劃分
    • 美國
    • 加拿大

第7章 歐洲犬類疫苗市場分析：洞察與預測（2021-2034）

  • 依國家劃分
    • 德國
    • 英國
    • 法國
    • 義大利
    • 西班牙
    • 斯堪的納維亞
    • 其他歐洲國家

第8章 亞太犬類疫苗市場分析：洞察與預測（2021-2034）

  • 依國家劃分
    • 中國
    • 日本
    • 印度
    • 澳洲
    • 東南亞
    • 亞太其他地區

第9章 拉丁美洲犬類疫苗市場分析：洞察與預測（2021-2034）

  • 依國家劃分
    • 巴西
    • 墨西哥
    • 拉丁美洲其他地區

第10章 中東與非洲犬類疫苗市場分析：洞察與預測（2021-2034）

  • 依國家劃分
    • GCC國家
    • 南非
    • 中東和非洲其他地區

第11章 競爭分析

  • 全球市場佔有率分析（2025）
  • 公司簡介
  • Elanco
  • Boehringer Ingelheim International GmbH
  • Virbac
  • Merck &Co., Inc.
  • Zoetis Services LLC
  • Ceva
  • Bioveta, a.s.
  • Indian Immunologicals Ltd.
  • HIPRA
  • Brilliant Bio Pharma（India）
Product Code: FBI113897

Growth Factors of canine vaccines Market

The global canine vaccines market was valued at USD 1.95 billion in 2025 and is projected to grow to USD 2.05 billion in 2026, eventually reaching USD 3.64 billion by 2034, reflecting a CAGR of 7.42% during the forecast period. North America dominated the market in 2025 with a 44.85% share, owing to advanced veterinary healthcare infrastructure, rising pet ownership, and strong awareness regarding canine disease prevention. The market is witnessing robust growth driven by the humanization of pets, increasing disposable income, and the growing adoption of preventive healthcare for dogs.

Leading companies in the market include Zoetis Services LLC, Merck & Co., Inc., Elanco, Boehringer Ingelheim International GmbH, Virbac, Ceva, Bioveta a.s., Indian Immunologicals Ltd., HIPRA, and Brilliant Bio Pharma, offering innovative vaccination solutions and expanding footprints globally. Recent research developments, such as Yale School of Medicine's cancer vaccine targeting canine EGFR/HER2 proteins in March 2024, underscore the increasing focus on novel vaccines for canine health.

Market Dynamics

Drivers: Rising pet ownership worldwide and growing willingness among pet owners to invest in advanced healthcare for dogs are primary drivers of market growth. In September 2022, the Global Animal Health Association reported around 85 million pet dogs in U.S. households, highlighting the potential for vaccine adoption. Increasing awareness about preventing diseases such as kennel cough, Lyme disease, and canine influenza further accelerates market growth.

Restraints: Vaccine hesitancy among dog owners poses a significant challenge. Concerns over vaccine safety, side effects, and the perceived necessity of routine vaccination reduce adoption rates. As per GAVI in January 2025, 4% of dogs and 12% of cats remained unvaccinated against rabies, reflecting ongoing resistance and market limitations.

Opportunities: Development and approval of novel combination vaccines offer broad-spectrum protection against multiple diseases. In July 2025, Elanco received USDA approval for TruCan Ultra CIV H3N2/H3N8, a canine influenza combination vaccine using PureFil technology. Such innovations improve convenience, reduce adverse reactions, and enhance comprehensive disease prevention.

Challenges: Decline in veterinary visits and shortage of skilled professionals affect market growth. Between 2021-2023, client visits fell by 2.7%, while a shortage of approximately 15,000 veterinarians exists globally compared to projected needs by 2030. These factors hamper vaccine adoption and present challenges for industry stakeholders.

Market Trends

The development of easy-to-administer vaccines, such as intranasal vaccines, is a growing trend. These vaccines reduce stress for pets and enable quick immune responses without specialized personnel. For instance, in March 2025, Zoetis Services LLC launched Vanguard B Intranasal vaccine, targeting Bordetella bronchiseptica (kennel cough), reflecting a shift toward efficient, user-friendly vaccination solutions.

Segmentation Analysis

By Technology:

  • Inactivated vaccines dominate due to strong safety profiles and practitioner acceptance. For example, in November 2024, Boehringer Ingelheim launched Eurican L4, protecting against leptospirosis.
  • Live attenuated vaccines offer long-lasting immunity with fewer boosters. Merck's NOBIVAC CANINE 1-DAPPv combines protection against multiple viruses.
  • Recombinant and other vaccines are growing due to safer, precise targeting.

By Disease Type:

  • Canine influenza leads due to rising cases and new approvals, e.g., NOBIVAC NXT Canine Flu H3N2 in June 2024.
  • Rabies remains significant, with global vaccination programs. In Bangladesh, 2.25 million doses were used to vaccinate 81.57% of stray dogs by June 2022.
  • Lyme disease and leptospirosis are also growing, driven by increasing disease incidence and preventive care adoption.

By Route of Administration:

  • Oral vaccines dominate due to ease of use for veterinarians and pets. Merck launched Nobivac Intra-Trac Oral BbPi in September 2022.
  • Intranasal vaccines are expanding, providing convenience and reduced stress.
  • Parenteral vaccines maintain significant market presence due to government-supported vaccination programs.

By Distribution Channel:

  • Veterinary hospitals lead due to advanced facilities and pet owner preference. For instance, Royal Veterinary College's Beaumont Sainsbury Animal Hospital earned Dog Friendly Clinic accreditation in August 2025.
  • Veterinary clinics are growing with AI-assisted solutions like VetRec partnered with Bond Vet in January 2025.
  • Pharmacies & drug stores and other channels grow moderately.

Regional Outlook

  • North America: Valued at USD 0.88 billion in 2025, led by the U.S. with advanced healthcare and government support.
  • Europe: Significant growth, driven by increasing pet ownership; in the U.K., 28% of adults own dogs (PDSA 2024).
  • Asia Pacific: Expected to witness the highest CAGR, supported by emerging markets and strategic expansions, e.g., Bioveta partnered with Vetina Healthcare in September 2024 in India.
  • Latin America & Middle East & Africa: Moderate growth, propelled by government vaccination initiatives, e.g., Boeringer Ingelheim's rabies drive in Kenya, December 2024.

Competitive Landscape

The market is semi-fragmented, with leading companies focusing on product launches, R&D, and strategic collaborations. Key players include Zoetis, Merck, Elanco, Boehringer Ingelheim, Virbac, Ceva, Bioveta, IIL, HIPRA, and Brilliant Bio Pharma. Recent industry developments include:

  • August 2025: Bioveta launched Biocan vaccines in Venezuela.
  • November 2024: Ceva established a new vaccine facility in Hungary.
  • July 2024: IIL conducted nationwide anti-rabies vaccination drives in India.

Conclusion

The global canine vaccines market is expected to grow from USD 1.95 billion in 2025 to USD 2.05 billion in 2026, reaching USD 3.64 billion by 2034 at a CAGR of 7.42%. Growth is driven by rising pet ownership, humanization of pets, preventive healthcare adoption, and government initiatives. North America dominates, while Asia Pacific exhibits the highest CAGR. Despite challenges such as vaccine hesitancy and professional shortages, innovations in combination vaccines, intranasal delivery, and strategic expansions are set to sustain market growth over the forecast period.

Segmentation By Technology

  • Inactivated
  • Live Attenuated
  • Recombinant
  • Others

By Disease Type

  • Canine Influenza
  • Lyme Disease
  • Rabies
  • Leptospirosis
  • Others

By Route of Administration

  • Oral
  • Parenteral
  • Intranasal

By Distribution Channel

  • Veterinary Hospitals
  • Veterinary Clinics
  • Pharmacies & Drug Stores
  • Others

By Region

  • North America (By Technology, By Disease Type, By Route of Administration, By Distribution Channel, By Country/ Sub-Region)
    • U.S.
    • Canada
  • Europe (By Technology, By Disease Type, By Route of Administration, By Distribution Channel, By Country/ Sub-Region)
    • U.K.
    • Germany
    • France
    • Italy
    • Spain
    • Scandinavia
    • Rest of Europe
  • Asia Pacific (By Technology, By Disease Type, By Route of Administration, By Distribution Channel, By Country/ Sub-Region)
    • Japan
    • China
    • India
    • Australia
    • Southeast Asia
    • Rest of Asia Pacific
  • Latin America (By Technology, By Disease Type, By Route of Administration, By Distribution Channel, By Country/ Sub-Region)
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa (By Technology, By Disease Type, By Route of Administration, By Distribution Channel, By Country/ Sub-Region)
    • GCC
    • South Africa
    • Rest of the Middle East & Africa

Table of Content

1. Introduction

  • 1.1. Research Scope
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
  • 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Market Trends

4. Key Insights

  • 4.1. Overview of Canine Diseases by Key Countries, By Key Countries/ Region, 2025
  • 4.2. Regulatory Scenario by Key Countries/ Region, 2025
  • 4.3. Overview of Vaccination for Canine Diseases
  • 4.4. New Technology Launches, By Key Players
  • 4.5. Key Industry Developments (Mergers, Acquisitions, Partnerships, etc.)

5. Global Canine Vaccines Market Analysis, Insights and Forecast, 2021-2034

  • 5.1. Market Analysis, Insights and Forecast - By Technology
    • 5.1.1. Inactivated
    • 5.1.2. Live Attenuated
    • 5.1.3. Recombinant
    • 5.1.4. Others
  • 5.2. Market Analysis, Insights and Forecast - By Disease Type
    • 5.2.1. Canine Influenza
    • 5.2.2. Lyme Disease
    • 5.2.3. Rabies
    • 5.2.4. Leptospirosis
    • 5.2.5. Others
  • 5.3. Market Analysis, Insights and Forecast - By Route of Administration
    • 5.3.1. Oral
    • 5.3.2. Parenteral
    • 5.3.3. Intranasal
  • 5.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 5.4.1. Veterinary Hospitals
    • 5.4.2. Veterinary Clinics
    • 5.4.3. Pharmacies & Drug Stores
    • 5.4.4. Others
  • 5.5. Market Analysis, Insights and Forecast - Region
    • 5.5.1. North America
    • 5.5.2. Europe
    • 5.5.3. Asia Pacific
    • 5.5.4. Latin America
    • 5.5.5. Middle East & Africa

6. North America Canine Vaccines Market Analysis, Insights and Forecast, 2021-2034

  • 6.1. Market Analysis, Insights and Forecast - By Technology
    • 6.1.1. Inactivated
    • 6.1.2. Live Attenuated
    • 6.1.3. Recombinant
    • 6.1.4. Others
  • 6.2. Market Analysis, Insights and Forecast - By Disease Type
    • 6.2.1. Canine Influenza
    • 6.2.2. Lyme Disease
    • 6.2.3. Rabies
    • 6.2.4. Leptospirosis
    • 6.2.5. Others
  • 6.3. Market Analysis, Insights and Forecast - By Route of Administration
    • 6.3.1. Oral
    • 6.3.2. Parenteral
    • 6.3.3. Intranasal
  • 6.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 6.4.1. Veterinary Hospitals
    • 6.4.2. Veterinary Clinics
    • 6.4.3. Pharmacies & Drug Stores
    • 6.4.4. Others
  • 6.5. Market Analysis, Insights and Forecast - By Country
    • 6.5.1. U.S.
    • 6.5.2. Canada

7. Europe Canine Vaccines Market Analysis, Insights and Forecast, 2021-2034

  • 7.1. Market Analysis, Insights and Forecast - By Technology
    • 7.1.1. Inactivated
    • 7.1.2. Live Attenuated
    • 7.1.3. Recombinant
    • 7.1.4. Others
  • 7.2. Market Analysis, Insights and Forecast - By Disease Type
    • 7.2.1. Canine Influenza
    • 7.2.2. Lyme Disease
    • 7.2.3. Rabies
    • 7.2.4. Leptospirosis
    • 7.2.5. Others
  • 7.3. Market Analysis, Insights and Forecast - By Route of Administration
    • 7.3.1. Oral
    • 7.3.2. Parenteral
    • 7.3.3. Intranasal
  • 7.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 7.4.1. Veterinary Hospitals
    • 7.4.2. Veterinary Clinics
    • 7.4.3. Pharmacies & Drug Stores
    • 7.4.4. Others
  • 7.5. Market Analysis, Insights and Forecast - By Technology
    • 7.5.1. Inactivated
    • 7.5.2. Live Attenuated
    • 7.5.3. Recombinant
    • 7.5.4. Others
  • 7.6. Market Analysis, Insights and Forecast - By Disease Type
    • 7.6.1. Canine Influenza
    • 7.6.2. Lyme Disease
    • 7.6.3. Rabies
    • 7.6.4. Leptospirosis
    • 7.6.5. Others
  • 7.7. Market Analysis, Insights and Forecast - By Route of Administration
    • 7.7.1. Oral
    • 7.7.2. Parenteral
    • 7.7.3. Intranasal
  • 7.8. Market Analysis, Insights and Forecast - By Distribution Channel
    • 7.8.1. Veterinary Hospitals
    • 7.8.2. Veterinary Clinics
    • 7.8.3. Pharmacies & Drug Stores
    • 7.8.4. Others
  • 7.9. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 7.9.1. Germany
    • 7.9.2. U.K.
    • 7.9.3. France
    • 7.9.4. Italy
    • 7.9.5. Spain
    • 7.9.6. Scandinavia
    • 7.9.7. Rest of Europe

8. Asia Pacific Canine Vaccines Market Analysis, Insights and Forecast, 2021-2034

  • 8.1. Market Analysis, Insights and Forecast - By Technology
    • 8.1.1. Inactivated
    • 8.1.2. Live Attenuated
    • 8.1.3. Recombinant
    • 8.1.4. Others
  • 8.2. Market Analysis, Insights and Forecast - By Disease Type
    • 8.2.1. Canine Influenza
    • 8.2.2. Lyme Disease
    • 8.2.3. Rabies
    • 8.2.4. Leptospirosis
    • 8.2.5. Others
  • 8.3. Market Analysis, Insights and Forecast - By Route of Administration
    • 8.3.1. Oral
    • 8.3.2. Parenteral
    • 8.3.3. Intranasal
  • 8.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 8.4.1. Veterinary Hospitals
    • 8.4.2. Veterinary Clinics
    • 8.4.3. Pharmacies & Drug Stores
    • 8.4.4. Others
  • 8.5. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 8.5.1. China
    • 8.5.2. Japan
    • 8.5.3. India
    • 8.5.4. Australia
    • 8.5.5. Southeast Asia
    • 8.5.6. Rest of Asia Pacific

9. Latin America Canine Vaccines Market Analysis, Insights and Forecast, 2021-2034

  • 9.1. Market Analysis, Insights and Forecast - By Technology
    • 9.1.1. Inactivated
    • 9.1.2. Live Attenuated
    • 9.1.3. Recombinant
    • 9.1.4. Others
  • 9.2. Market Analysis, Insights and Forecast - By Disease Type
    • 9.2.1. Canine Influenza
    • 9.2.2. Lyme Disease
    • 9.2.3. Rabies
    • 9.2.4. Leptospirosis
    • 9.2.5. Others
  • 9.3. Market Analysis, Insights and Forecast - By Route of Administration
    • 9.3.1. Oral
    • 9.3.2. Parenteral
    • 9.3.3. Intranasal
  • 9.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 9.4.1. Veterinary Hospitals
    • 9.4.2. Veterinary Clinics
    • 9.4.3. Pharmacies & Drug Stores
    • 9.4.4. Others
  • 9.5. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 9.5.1. Brazil
    • 9.5.2. Mexico
    • 9.5.3. Rest of Latin America

10. Middle East & Africa Canine Vaccines Market Analysis, Insights and Forecast, 2021-2034

  • 10.1. Market Analysis, Insights and Forecast - By Technology
    • 10.1.1. Inactivated
    • 10.1.2. Live Attenuated
    • 10.1.3. Recombinant
    • 10.1.4. Others
  • 10.2. Market Analysis, Insights and Forecast - By Disease Type
    • 10.2.1. Canine Influenza
    • 10.2.2. Lyme Disease
    • 10.2.3. Rabies
    • 10.2.4. Leptospirosis
    • 10.2.5. Others
  • 10.3. Market Analysis, Insights and Forecast - By Route of Administration
    • 10.3.1. Oral
    • 10.3.2. Parenteral
    • 10.3.3. Intranasal
  • 10.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 10.4.1. Veterinary Hospitals
    • 10.4.2. Veterinary Clinics
    • 10.4.3. Pharmacies & Drug Stores
    • 10.4.4. Others
  • 10.5. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 10.5.1. GCC
    • 10.5.2. South Africa
    • 10.5.3. Rest of Middle East & Africa

11. Competitive Analysis

  • 11.1. Global Market Share Analysis (2025)
  • 11.2. Company Profiles (Overview, Products, SWOT Analysis, Recent Developments, Strategies, Financials (Based on Availability))
    • 11.2.1. Elanco
    • 11.2.2. Boehringer Ingelheim International GmbH
    • 11.2.3. Virbac
    • 11.2.4. Merck & Co., Inc.
    • 11.2.5. Zoetis Services LLC
    • 11.2.6. Ceva
    • 11.2.7. Bioveta, a.s.
    • 11.2.8. Indian Immunologicals Ltd.
    • 11.2.9. HIPRA
    • 11.2.10. Brilliant Bio Pharma (India)

List of Tables

  • Table 1: Global Canine Vaccines Market Revenue (USD billion) Forecast, by Technology, 2021-2034
  • Table 2: Global Canine Vaccines Market Revenue (USD billion) Forecast, by Disease Type, 2021-2034
  • Table 3: Global Canine Vaccines Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
  • Table 4: Global Canine Vaccines Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 5: Global Canine Vaccines Market Revenue (USD billion) Forecast, by Region, 2021-2034
  • Table 6: North America Canine Vaccines Market Revenue (USD billion) Forecast, by Technology, 2021-2034
  • Table 7: North America Canine Vaccines Market Revenue (USD billion) Forecast, by Disease Type, 2021-2034
  • Table 8: North America Canine Vaccines Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
  • Table 9: North America Canine Vaccines Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 10: North America Canine Vaccines Market Revenue (USD billion) Forecast, By Country, 2021-2034
  • Table 11: Europe Canine Vaccines Market Revenue (USD billion) Forecast, by Technology, 2021-2034
  • Table 12: Europe Canine Vaccines Market Revenue (USD billion) Forecast, by Disease Type, 2021-2034
  • Table 13: Europe Canine Vaccines Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
  • Table 14: Europe Canine Vaccines Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 15: Europe Canine Vaccines Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 16: Asia Pacific Canine Vaccines Market Revenue (USD billion) Forecast, by Technology, 2021-2034
  • Table 17: Asia Pacific Canine Vaccines Market Revenue (USD billion) Forecast, by Disease Type, 2021-2034
  • Table 18: Asia Pacific Canine Vaccines Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
  • Table 19: Asia Pacific Canine Vaccines Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 20: Asia Pacific Canine Vaccines Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 21: Latin America Canine Vaccines Market Revenue (USD billion) Forecast, by Technology, 2021-2034
  • Table 22: Latin America Canine Vaccines Market Revenue (USD billion) Forecast, by Disease Type, 2021-2034
  • Table 23: Latin America Canine Vaccines Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
  • Table 24: Latin America Canine Vaccines Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 25: Latin America Canine Vaccines Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 26: Middle East & Africa Canine Vaccines Market Revenue (USD billion) Forecast, by Technology, 2021-2034
  • Table 27: Middle East & Africa Canine Vaccines Market Revenue (USD billion) Forecast, by Disease Type, 2021-2034
  • Table 28: Middle East & Africa Canine Vaccines Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
  • Table 29: Middle East & Africa Canine Vaccines Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 30: Middle East & Africa Canine Vaccines Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034

List of Figures

  • Figure 1: Global Canine Vaccines Market Revenue Breakdown (USD billion, %) by Region, 2025 & 2034
  • Figure 2: Global Canine Vaccines Market Value Share (%), by Technology, 2025 & 2034
  • Figure 3: Global Canine Vaccines Market Value Share (%), by Disease Type, 2025 & 2034
  • Figure 4: Global Canine Vaccines Market Value Share (%), by Route of Administration, 2025 & 2034
  • Figure 5: Global Canine Vaccines Market Value Share (%), by Distribution Channel, 2025 & 2034
  • Figure 6: Global Canine Vaccines Market Value Share (%), by Region, 2025 & 2034
  • Figure 7: North America Canine Vaccines Market Value (USD billion), by Technology, 2025 & 2034
  • Figure 8: North America Canine Vaccines Market Value Share (%), by Technology, 2025
  • Figure 9: North America Canine Vaccines Market Value (USD billion), by Disease Type, 2025 & 2034
  • Figure 10: North America Canine Vaccines Market Value Share (%), by Disease Type, 2025
  • Figure 11: North America Canine Vaccines Market Value (USD billion), by Route of Administration, 2025 & 2034
  • Figure 12: North America Canine Vaccines Market Value Share (%), by Route of Administration, 2025
  • Figure 13: North America Canine Vaccines Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 14: North America Canine Vaccines Market Value Share (%), by Distribution Channel, 2025
  • Figure 15: North America Canine Vaccines Market Value (USD billion), By Country, 2025 & 2034
  • Figure 16: North America Canine Vaccines Market Value Share (%), By Country, 2025
  • Figure 17: Europe Canine Vaccines Market Value (USD billion), by Technology, 2025 & 2034
  • Figure 18: Europe Canine Vaccines Market Value Share (%), by Technology, 2025
  • Figure 19: Europe Canine Vaccines Market Value (USD billion), by Disease Type, 2025 & 2034
  • Figure 20: Europe Canine Vaccines Market Value Share (%), by Disease Type, 2025
  • Figure 21: Europe Canine Vaccines Market Value (USD billion), by Route of Administration, 2025 & 2034
  • Figure 22: Europe Canine Vaccines Market Value Share (%), by Route of Administration, 2025
  • Figure 23: Europe Canine Vaccines Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 24: Europe Canine Vaccines Market Value Share (%), by Distribution Channel, 2025
  • Figure 25: Europe Canine Vaccines Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 26: Europe Canine Vaccines Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 27: Asia Pacific Canine Vaccines Market Value (USD billion), by Technology, 2025 & 2034
  • Figure 28: Asia Pacific Canine Vaccines Market Value Share (%), by Technology, 2025
  • Figure 29: Asia Pacific Canine Vaccines Market Value (USD billion), by Disease Type, 2025 & 2034
  • Figure 30: Asia Pacific Canine Vaccines Market Value Share (%), by Disease Type, 2025
  • Figure 31: Asia Pacific Canine Vaccines Market Value (USD billion), by Route of Administration, 2025 & 2034
  • Figure 32: Asia Pacific Canine Vaccines Market Value Share (%), by Route of Administration, 2025
  • Figure 33: Asia Pacific Canine Vaccines Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 34: Asia Pacific Canine Vaccines Market Value Share (%), by Distribution Channel, 2025
  • Figure 35: Asia Pacific Canine Vaccines Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 36: Asia Pacific Canine Vaccines Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 37: Latin America Canine Vaccines Market Value (USD billion), by Technology, 2025 & 2034
  • Figure 38: Latin America Canine Vaccines Market Value Share (%), by Technology, 2025
  • Figure 39: Latin America Canine Vaccines Market Value (USD billion), by Disease Type, 2025 & 2034
  • Figure 40: Latin America Canine Vaccines Market Value Share (%), by Disease Type, 2025
  • Figure 41: Latin America Canine Vaccines Market Value (USD billion), by Route of Administration, 2025 & 2034
  • Figure 42: Latin America Canine Vaccines Market Value Share (%), by Route of Administration, 2025
  • Figure 43: Latin America Canine Vaccines Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 44: Latin America Canine Vaccines Market Value Share (%), by Distribution Channel, 2025
  • Figure 45: Latin America Canine Vaccines Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 46: Latin America Canine Vaccines Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 47: Middle East & Africa Canine Vaccines Market Value (USD billion), by Technology, 2025 & 2034
  • Figure 48: Middle East & Africa Canine Vaccines Market Value Share (%), by Technology, 2025
  • Figure 49: Middle East & Africa Canine Vaccines Market Value (USD billion), by Disease Type, 2025 & 2034
  • Figure 50: Middle East & Africa Canine Vaccines Market Value Share (%), by Disease Type, 2025
  • Figure 51: Middle East & Africa Canine Vaccines Market Value (USD billion), by Route of Administration, 2025 & 2034
  • Figure 52: Middle East & Africa Canine Vaccines Market Value Share (%), by Route of Administration, 2025
  • Figure 53: Middle East & Africa Canine Vaccines Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 54: Middle East & Africa Canine Vaccines Market Value Share (%), by Distribution Channel, 2025
  • Figure 55: Middle East & Africa Canine Vaccines Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 56: Middle East & Africa Canine Vaccines Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 57: Global Canine Vaccines Market Share (%), By Company, 2025